Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202GlobeNewsWire • 09/09/26
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline ProgressGlobeNewsWire • 08/05/26
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/10/26
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer StudyBenzinga • 06/15/26
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76GlobeNewsWire • 06/15/26
Context Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/27/26
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202GlobeNewsWire • 05/18/26
Context Therapeutics Reports First Quarter 2026 Operating and Financial ResultsGlobeNewsWire • 05/06/26
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerGlobeNewsWire • 04/02/26
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewsWire • 03/19/26
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/16/26
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual MeetingGlobeNewsWire • 11/07/25
Context Therapeutics Reports Third Quarter 2025 Operating and Financial ResultsGlobeNewsWire • 11/05/25
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical OfficerGlobeNewsWire • 10/28/25
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual MeetingGlobeNewsWire • 10/06/25
Context Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsGlobeNewsWire • 08/06/25
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingGlobeNewsWire • 06/02/25
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerGlobeNewsWire • 05/29/25
Context Therapeutics Reports First Quarter 2025 Operating and Financial ResultsGlobeNewsWire • 05/07/25